Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.

Liver Unit, Cardarelli Hospital, Naples, Italy.
Digestive and Liver Disease (Impact Factor: 3.16). 05/2012; 44(9):788-92. DOI: 10.1016/j.dld.2012.04.001
Source: PubMed

ABSTRACT Sorafenib is currently the only approved systemic treatment for hepatocellular carcinoma.
to evaluate safety and effectiveness of sorafenib in the field of practice.
We report a single-centre experience on 116 advanced hepatocellular carcinoma patients treated with sorafenib between February 2008 and March 2011. Every 4 weeks, adverse events were graded using Common Toxicity Criteria version 3.0, and every 3 months tumour response was assessed according to modified Response Evaluation Criteria in Solid Tumours for hepatocellular carcinoma.
Cirrhosis was present in 95.7% of patients (83.6% Child-Pugh A class), hepatitis C was the main etiological factor. Median therapy duration was 3 months and median daily dose was 642 mg. Median time-to-radiological progression in the per-protocol population was 12 months and median overall survival in the intention-to-treat population was 13 months. 91.4% of patients experienced mild adverse events (grade 1 or 2), the most frequent were gastrointestinal and dermatological. Jaundice and bleeding were the main causes of definitive drug discontinuation. 3-month overall disease control rate was 70.6%: stable disease in 37.2%, partial response in 30.8%, and complete response in 2.6% patients. The 3-month radiological response correlated with overall survival.
In daily clinical practice, sorafenib confirmed its safety and efficacy in hepatocellular carcinoma patients.